Genentech, a subsidiary of the Roche Group, partnered with Parvus Therapeutics to develop Navacim™ Therapeutics for the treatment of autoimmune diseases. Parvus Therapeutics will receive $800 million in the form of upfront and milestone payments, as well as royalties on net sales. Roche's most recent patent publication in the AI Biotech sector is directed to continuously monitoring glucose levels for helping patients with diabetes, an autoimmune disease.
